SCHEMBL3882407

SCHEMBL3882407

Cc1ccc(NC(=O)c2cccc(CNS(=O)(=O)c3ccc4ccccc4c3)c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR17 Q13304 1/20 0.64
CYP19A1 P11511 2/20 0.61
MAPT P10636 2/20 0.60
ENPP2 Q13822 1/20 0.57
POLB P06746 2/20 0.56
RECQL P46063 2/20 0.56
RAB9A P51151 3/20 0.56
NPC1 O15118 2/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
KCNA5 P22460 1/20 0.53
KAT6A Q92794 2/20 0.53
F2 P00734 1/20 0.52
F10 P00742 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
LMNA P02545 1/20 0.51
GPR27 Q9NS67 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884841 0.86 GPR17 (0.68) GPR17CYP19A1MAPTPOLBRECQL
SCHEMBL3873257 0.82 ENPP2 (0.55) MAPTENPP2POLBRAB9ANPC1
SCHEMBL3871576 0.80 POLB (0.78) CYP19A1MAPTPOLBRECQLMEN1
SCHEMBL3876577 0.78 CYP19A1 (0.67) CYP19A1MAPTPOLBRECQLMEN1
SCHEMBL3872817 0.77 HTT (0.68) CYP19A1POLBRAB9AF2F10
SCHEMBL28003778 0.77 CYP19A1 (0.70) CYP19A1MAPTPOLBRECQLMEN1
SCHEMBL3876662 0.76 HSD11B1 (0.60) CYP19A1POLBRAB9ANPC1KMT2A
SCHEMBL27450611 0.76 CYP19A1 (0.74) GPR17CYP19A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL3879290 0.76 ALDH1A1 (0.66) CYP19A1POLBNPC1MEN1KMT2A
SCHEMBL12447826 0.75 NPC1 (0.82) MAPTENPP2POLBRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 GPR17 3455/4885CYP19A1 23/4885MAPT 4169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.